重组组织型纤溶酶原激活剂的实验性粘连预防
Experimental adhesion prophylaxis with recombinant tissue plasminogen activator.
作者信息
Vipond M N, Whawell S A, Scott-Coombes D M, Thompson J N, Dudley H A
机构信息
Academic Surgical Unit, St Mary's Hospital, London.
出版信息
Ann R Coll Surg Engl. 1994 Nov;76(6):412-5.
The deposition of fibrin in the peritoneal cavity leads to fibrous adhesion formation. Recombinant tissue plasminogen activator (rtPA), delivered locally, was investigated as a method of preventing adhesion formation. Six standardised areas of peritoneal ischaemia were formed in each of 36 male Wistar rats randomised to three intraperitoneal treatments: (A) no treatment control; (B) carboxymethylcellulose gel; (C) rtPA-carboxymethylcellulose gel combination. At 1 week all animals underwent relaparotomy and the number of ischaemic sites with an adhesion counted by an independent observer. rtPA-treated animals formed fewer adhesions compared with gel alone or controls (median number of adhesions 1.5 versus 2.5 versus 5, P < 0.001, ANOVA). Intraperitoneal rtPA in a slow-release formulation is able to reduce adhesion formation significantly in an animal model and may prove to have clinical benefit.
纤维蛋白在腹腔内沉积会导致纤维粘连形成。局部递送的重组组织型纤溶酶原激活剂（rtPA）被作为一种预防粘连形成的方法进行研究。将36只雄性Wistar大鼠随机分为三种腹腔内治疗组，每组大鼠均形成六个标准化的腹膜缺血区域：（A）不治疗对照组；（B）羧甲基纤维素凝胶组；（C）rtPA-羧甲基纤维素凝胶联合组。在第1周时，所有动物均接受再次剖腹手术，由一名独立观察者对存在粘连的缺血部位数量进行计数。与单独使用凝胶组或对照组相比，rtPA治疗组动物形成的粘连较少（粘连中位数分别为1.5、2.5和5，P<0.001，方差分析）。缓释制剂的腹腔内rtPA能够在动物模型中显著减少粘连形成，可能具有临床益处。
Zotero 插件